
    
      The investigators designed a single center, open-label, prospective study that routinely
      administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory
      parameters to explore its efficacy and to observe changes in immune cell subsets and
      cytokines.

      Methods: Patients were divided into two groups. One received standard therapy, while another
      one administrate with low-does IL-2 plus standard therapy.
    
  